AI / ML Innovations Stock Price, News & Analysis

AI/ML Innovations (OTCQB:AIMLF) has successfully completed an oversubscribed non-brokered private placement, raising $2,128,595 through the issuance of 42,571,900 Units at $0.05 per Unit. Each Unit includes one common share and one warrant exercisable at $0.15 until September 22, 2030.

Notable insider participation included CEO Paul Duffy (5M Units), President Peter Kendall (500K Units), CPO Esmatullah Naikyar (120K Units), and major shareholder Sheldon Inwentash (26M Units). Additionally, the company extended the expiry date of 12,376,666 December 2023 Warrants to December 19, 2028, and granted 5,700,000 stock options to officers, employees, and consultants at $0.10 per share.

AI/ML Innovations (OTCQB:AIMLF) has announced plans for a non-brokered private placement offering of up to 31,000,000 units at $0.05 per unit, aiming to raise gross proceeds of up to $1.55 million.

Each unit consists of one common share and one warrant, with each warrant exercisable at $0.15 per share for a five-year term. The securities will have a four-month and one-day hold period. The company plans to use the proceeds for working capital requirements and will pay finder's fees to qualified finders. The private placement remains subject to necessary approvals, including from the Canadian Securities Exchange.

AI/ML Innovations (OTCQB:AIMLF) has filed an amended and restated management's discussion and analysis (MD&A) for the periods ending January 31, 2025, following a review by the British Columbia Securities Commission. The amended filing addresses several disclosure deficiencies.

The enhanced disclosure includes details about new strategic initiatives, R&D activities, operational results, and the acquisition of Quantum Sciences Ltd. Additional information covers related party payments, an exit agreement with Tech2Heal, and other minor updates. The complete Amended MD&A is accessible on SEDAR+.

AI/ML Innovations (OTCQB:AIMLF) has announced the completion of its restructuring related to the previously acquired Quantum Sciences Ltd. The restructuring, which follows the original acquisition from December 23, 2024, includes key modifications to the initially announced terms.

Two notable changes from the original restructuring announcement include: (1) the non-execution of a planned reseller agreement with Mark Orsmond, and (2) the retention of all intellectual property rights and interests in the "meApp" application by AIML, rather than transferring them to Mark Orsmond as previously planned.

AI/ML Innovations (AIML) has strengthened its intellectual property portfolio by filing provisional patent applications with the USPTO through its subsidiary Neural Cloud Solutions. The patents cover advanced neural network architectures and cloud-based ECG signal optimization workflows, specifically protecting their MaxYield and CardioYield platforms. The technology includes AI-driven ECG signal processing, cloud-native workflows, and a dynamic reporting engine that supports clinical workflows. The patent filings aim to protect both algorithmic foundations and deployment infrastructure, positioning AIML strategically in the AI-assisted cardiology market. The company's CardioYield system enables structured outputs including rhythm classifications, interval measurements, and reviewable event flags, designed to enhance clinician review across various clinical contexts.

AI/ML Innovations' subsidiary Neural Cloud Solutions has signed a Letter of Intent with Circular Health Limited to integrate and license its MaxYield™ ECG signal-processing platform. The partnership will enhance Circular Health's smart ring device with improved ECG signal clarity through a cloud-based API integration. The agreement includes a per-user SaaS licensing model, with commercial launch targeted for September 2025. MaxYield™ is expected to provide higher data yield, scalable workflow, and enable expansion into medical markets as it progresses through FDA 510(k) clearance. The technology will allow Circular Health to capture more usable data, enhance measurement precision, and redeploy resources from signal cleaning to advanced analytics and patient engagement.

AIML (AIMLF) has announced the formation of its Medical Advisory Board to guide the development and implementation of its AI-powered ECG signal-processing platforms MaxYield™ and CardioYield™. The board comprises six distinguished cardiovascular experts from leading institutions, including the University of Toronto and University of British Columbia. Peter Kendall, AIML's President and Chief Commercialization Officer, will chair the board, leveraging his 20+ years of experience in health technology commercialization.

The advisory board will focus on steering clinical direction, trial design, and real-world deployment of AIML's flagship AI platforms. Simultaneously, the company has launched its redesigned corporate website, AIML.Health, serving as an interactive platform for stakeholders.

AI/ML Innovations (AIML) has submitted a 510(k) premarket notification to the FDA for its MaxYield™ platform, a cloud-native solution designed to enhance ECG signal quality. The platform uses proprietary neural network algorithms to reduce noise and improve waveform clarity in ECG signals across 1- to 12-lead configurations for adult patients 18 and older.

MaxYield is compatible with both hospital-grade systems and mobile devices, targeting signal distortions common in mobile, wearable, and dynamic clinical environments. This submission follows AIML's prior Device Master File (MAF) filing, which could facilitate future collaborations with manufacturers for device integration.

Additionally, AIML granted 800,000 stock options to directors and consultants at an exercise price of $0.105, vesting quarterly over one year with a five-year expiration.

AIML Innovations (OTCQB: AIMLF) has appointed Michael Diamond to its Board of Directors, effective immediately. Diamond, who serves as the President of the Ontario Progressive Conservative Party and Principal of Upstream Strategy Group, brings extensive expertise in political strategy, regulatory affairs, and stakeholder engagement. The appointment aims to strengthen AIML's expansion of AI-powered health technologies across regulated markets.

As a public affairs and strategic communications expert, Diamond's experience at the intersection of politics, business, and innovation will support AIML's efforts to build partnerships and navigate policy environments. The company, through its subsidiaries and strategic partnerships, focuses on AI and machine learning applications in digital health and wellbeing solutions.